Ophthalmic composition for the treatment of visual disorders
US-2024335458-A1 · Oct 10, 2024 · US
US12083132B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-12083132-B1 |
| Application number | US-202318121280-A |
| Country | US |
| Kind code | B1 |
| Filing date | Mar 14, 2023 |
| Priority date | Jul 10, 2015 |
| Publication date | Sep 10, 2024 |
| Grant date | Sep 10, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical formulation comprising: (a) a therapeutically effective amount of a compound of the formula below or a salt thereof, and (b) a pharmaceutically acceptable excipient. 2. The pharmaceutical formulation of claim 1 , wherein the formulation is a particle, bead, tablet, capsule, or pill. 3. The pharmaceutical formulation of claim 1 , wherein the formulation is a lotion, liquid, or gel. 4. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises an additional antibiotic. 5. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises a steroid. 6. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises an anti-inflammatory agent. 7. A method of treating or preventing a bacterial infection in a subject comprising administering to the subject an effective amount of a pharmaceutical formulation comprising: (a) a therapeutically effective amount of a compound of the formula below or a salt thereof, and (b) a pharmaceutically acceptable excipient. 8. The method of claim 7 , wherein the subject has an abscess, furuncle, cellulitis, folliculitis, atopic dermatitis, psoriasis, impetigo, septic arthritis, brain abscess, burn wound, venous ulcer, diabetic foot ulcer, surgical wound, carbuncle, or meningitis. 9. The method of claim 7 , wherein the subject has bacteremia, pneumonia, staphylococcal food poisoning, necrotizing pneumonia, necrotizing fasciitis, scaled skin syndrome, post-operation bacterial infection, medical device bacterial infection, bacterial infection of the skin, soft tissue bacterial infection, or toxic shock syndrome. 10. The method of claim 7 , wherein the bacterial infection is a toxin-mediated bacterial infection. 11. The method of claim 10 , wherein the toxin-mediated bacterial infection is a Staphylococcus -mediated bacterial infection. 12. The method of claim 7 , wherein administering comprises topical administration of the formulation. 13. The method of claim 7 , further comprising administering to the subject an additional antibiotic. 14. The method of claim 13 , wherein the formulation further comprises an additional antibiotic. 15. The method of claim 7 , further comprising administering to the subject a steroid. 16. The method of claim 15 , wherein the formulation further comprises a steroid. 17. The method of claim 7 , further comprising administering to the subject an anti-inflammatory agent. 18. The method of claim 17 , wherein the formulation further comprises an anti-inflammatory agent.
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak · CPC title
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
Antibacterial agents · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.